Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Poisoning | 5 | 2018 | 29 | 1.230 |
Why?
|
| Registries | 5 | 2018 | 571 | 0.970 |
Why?
|
| Drug Overdose | 6 | 2018 | 104 | 0.770 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2018 | 106 | 0.710 |
Why?
|
| Acetaminophen | 4 | 2013 | 36 | 0.660 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2016 | 22 | 0.630 |
Why?
|
| Referral and Consultation | 4 | 2017 | 246 | 0.550 |
Why?
|
| Toxicology | 4 | 2018 | 32 | 0.430 |
Why?
|
| Drug Hypersensitivity | 1 | 2013 | 16 | 0.400 |
Why?
|
| Analgesics | 1 | 2013 | 52 | 0.390 |
Why?
|
| Emergency Service, Hospital | 3 | 2013 | 563 | 0.390 |
Why?
|
| Hydrocarbons | 1 | 2011 | 6 | 0.360 |
Why?
|
| Inhalation Exposure | 1 | 2011 | 53 | 0.350 |
Why?
|
| Dibenzothiazepines | 1 | 2010 | 5 | 0.340 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 18 | 0.340 |
Why?
|
| Pneumonia | 1 | 2011 | 95 | 0.340 |
Why?
|
| Delirium | 1 | 2010 | 27 | 0.330 |
Why?
|
| Barium | 1 | 2009 | 7 | 0.330 |
Why?
|
| Hypokalemia | 1 | 2009 | 5 | 0.320 |
Why?
|
| Explosive Agents | 1 | 2009 | 4 | 0.320 |
Why?
|
| Occupational Exposure | 2 | 2012 | 287 | 0.310 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 483 | 0.300 |
Why?
|
| Antipsychotic Agents | 1 | 2010 | 243 | 0.290 |
Why?
|
| Intellectual Disability | 1 | 2009 | 145 | 0.270 |
Why?
|
| Male | 14 | 2018 | 18271 | 0.250 |
Why?
|
| Adult | 11 | 2018 | 10255 | 0.240 |
Why?
|
| Middle Aged | 9 | 2018 | 10090 | 0.230 |
Why?
|
| Adolescent | 7 | 2017 | 4034 | 0.230 |
Why?
|
| Humans | 22 | 2023 | 40217 | 0.220 |
Why?
|
| Aged | 8 | 2018 | 8182 | 0.210 |
Why?
|
| Angiotensinogen | 1 | 2023 | 2 | 0.210 |
Why?
|
| Antihypertensive Agents | 1 | 2023 | 92 | 0.200 |
Why?
|
| Porphyrias, Hepatic | 1 | 2022 | 1 | 0.200 |
Why?
|
| Hyperhomocysteinemia | 1 | 2022 | 3 | 0.200 |
Why?
|
| Female | 11 | 2018 | 20392 | 0.190 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 3136 | 0.170 |
Why?
|
| Time Factors | 3 | 2017 | 2422 | 0.170 |
Why?
|
| Hypertension | 1 | 2023 | 385 | 0.160 |
Why?
|
| Annual Reports as Topic | 1 | 2018 | 1 | 0.150 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2018 | 22 | 0.150 |
Why?
|
| Gadolinium | 1 | 2018 | 51 | 0.150 |
Why?
|
| Child | 5 | 2018 | 2856 | 0.140 |
Why?
|
| Infant | 3 | 2016 | 989 | 0.140 |
Why?
|
| Contrast Media | 1 | 2018 | 208 | 0.140 |
Why?
|
| Suicide, Attempted | 3 | 2016 | 78 | 0.140 |
Why?
|
| Hypnotics and Sedatives | 1 | 2016 | 34 | 0.130 |
Why?
|
| Young Adult | 5 | 2018 | 2877 | 0.130 |
Why?
|
| United States | 6 | 2018 | 4886 | 0.120 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 162 | 0.120 |
Why?
|
| Child, Preschool | 2 | 2017 | 1203 | 0.110 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2014 | 7 | 0.110 |
Why?
|
| Indans | 1 | 2014 | 7 | 0.110 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2014 | 19 | 0.110 |
Why?
|
| Drug Interactions | 2 | 2014 | 89 | 0.110 |
Why?
|
| Emergencies | 2 | 2013 | 56 | 0.110 |
Why?
|
| Antidotes | 2 | 2016 | 18 | 0.110 |
Why?
|
| Parkinson Disease | 1 | 2014 | 73 | 0.110 |
Why?
|
| Hydroquinones | 1 | 2013 | 8 | 0.100 |
Why?
|
| Skin Lightening Preparations | 1 | 2013 | 3 | 0.100 |
Why?
|
| Status Epilepticus | 1 | 2013 | 16 | 0.100 |
Why?
|
| Bleaching Agents | 1 | 2013 | 6 | 0.100 |
Why?
|
| Vomiting | 2 | 2010 | 25 | 0.100 |
Why?
|
| Sodium Hypochlorite | 1 | 2013 | 10 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 42 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 63 | 0.100 |
Why?
|
| Chemical Warfare Agents | 1 | 2012 | 3 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2014 | 833 | 0.090 |
Why?
|
| Mustard Gas | 1 | 2012 | 6 | 0.090 |
Why?
|
| Blister | 1 | 2012 | 13 | 0.090 |
Why?
|
| Cyclohexylamines | 1 | 2011 | 5 | 0.090 |
Why?
|
| Cyclohexanones | 1 | 2011 | 5 | 0.090 |
Why?
|
| Albuterol | 1 | 2011 | 12 | 0.090 |
Why?
|
| Methylprednisolone | 1 | 2011 | 21 | 0.090 |
Why?
|
| Kidney | 1 | 2013 | 275 | 0.090 |
Why?
|
| Acute Lung Injury | 1 | 2011 | 14 | 0.090 |
Why?
|
| Bronchodilator Agents | 1 | 2011 | 28 | 0.090 |
Why?
|
| Prednisone | 1 | 2011 | 62 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 2 | 0.090 |
Why?
|
| Self Report | 1 | 2013 | 270 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2014 | 3138 | 0.090 |
Why?
|
| Trazodone | 1 | 2010 | 3 | 0.090 |
Why?
|
| Clonidine | 1 | 2010 | 8 | 0.090 |
Why?
|
| Physostigmine | 1 | 2010 | 3 | 0.090 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2010 | 6 | 0.090 |
Why?
|
| Tachycardia | 1 | 2010 | 12 | 0.090 |
Why?
|
| Quetiapine Fumarate | 1 | 2010 | 8 | 0.090 |
Why?
|
| Hypotension | 1 | 2010 | 21 | 0.090 |
Why?
|
| Heart Block | 1 | 2010 | 18 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2011 | 45 | 0.080 |
Why?
|
| Cysteine | 1 | 2011 | 90 | 0.080 |
Why?
|
| Acetylcysteine | 1 | 2010 | 15 | 0.080 |
Why?
|
| Self-Injurious Behavior | 1 | 2010 | 30 | 0.080 |
Why?
|
| Prevalence | 1 | 2013 | 870 | 0.080 |
Why?
|
| Gastric Lavage | 1 | 2009 | 1 | 0.080 |
Why?
|
| Potassium | 1 | 2009 | 80 | 0.080 |
Why?
|
| Diarrhea | 1 | 2009 | 46 | 0.080 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 68 | 0.080 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2009 | 10 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 215 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2009 | 42 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2009 | 77 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2013 | 2863 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2009 | 288 | 0.070 |
Why?
|
| Depression | 1 | 2010 | 608 | 0.060 |
Why?
|
| Tetrazoles | 1 | 2023 | 9 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2023 | 45 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2023 | 19 | 0.050 |
Why?
|
| Vitamin B 6 | 1 | 2022 | 2 | 0.050 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2022 | 2 | 0.050 |
Why?
|
| Pyridoxine | 1 | 2022 | 3 | 0.050 |
Why?
|
| Sulfur | 1 | 2022 | 15 | 0.050 |
Why?
|
| Homocysteine | 1 | 2022 | 24 | 0.050 |
Why?
|
| Heme | 1 | 2022 | 27 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2023 | 367 | 0.050 |
Why?
|
| Methionine | 1 | 2022 | 49 | 0.050 |
Why?
|
| Folic Acid | 1 | 2022 | 33 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2023 | 307 | 0.050 |
Why?
|
| Prognosis | 2 | 2017 | 921 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 114 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 289 | 0.040 |
Why?
|
| Diet | 1 | 2023 | 440 | 0.040 |
Why?
|
| RNA Interference | 1 | 2023 | 558 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 600 | 0.040 |
Why?
|
| Weapons of Mass Destruction | 1 | 2018 | 1 | 0.040 |
Why?
|
| Demography | 1 | 2018 | 128 | 0.040 |
Why?
|
| Israel | 1 | 2017 | 14 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2018 | 90 | 0.030 |
Why?
|
| Pediatrics | 1 | 2018 | 159 | 0.030 |
Why?
|
| Toxiferine | 1 | 2016 | 1 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2022 | 795 | 0.030 |
Why?
|
| Sentinel Surveillance | 1 | 2016 | 13 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2016 | 32 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 74 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2017 | 355 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 463 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 966 | 0.030 |
Why?
|
| Lorazepam | 1 | 2013 | 6 | 0.030 |
Why?
|
| Phenobarbital | 1 | 2013 | 8 | 0.030 |
Why?
|
| Phenytoin | 1 | 2013 | 13 | 0.030 |
Why?
|
| Physical Therapy Modalities | 1 | 2013 | 19 | 0.030 |
Why?
|
| Ataxia | 1 | 2013 | 16 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2013 | 38 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2013 | 70 | 0.020 |
Why?
|
| Seizures | 1 | 2013 | 79 | 0.020 |
Why?
|
| Eating | 1 | 2013 | 115 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2013 | 134 | 0.020 |
Why?
|
| Poison Control Centers | 1 | 2012 | 4 | 0.020 |
Why?
|
| Fisheries | 1 | 2012 | 2 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2013 | 124 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2012 | 36 | 0.020 |
Why?
|
| New England | 1 | 2012 | 214 | 0.020 |
Why?
|
| Arabia | 1 | 2011 | 1 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 1479 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 13 | 0.020 |
Why?
|
| Nausea | 1 | 2010 | 24 | 0.020 |
Why?
|
| Anaphylaxis | 1 | 2010 | 19 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 270 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 89 | 0.020 |
Why?
|
| Safety | 1 | 2010 | 102 | 0.020 |
Why?
|
| Skin | 1 | 2012 | 274 | 0.020 |
Why?
|
| Drug Storage | 1 | 2009 | 21 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 220 | 0.020 |
Why?
|
| Alcoholism | 1 | 2011 | 219 | 0.020 |
Why?
|
| Internet | 1 | 2011 | 338 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2009 | 160 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 289 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 945 | 0.020 |
Why?
|
| Risk Factors | 1 | 2011 | 3141 | 0.010 |
Why?
|